m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04210)
Name
BMS-936557
Synonyms
Anti-CXCL10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Medarex/BMS; Anti-IP-10 antibody (iv, ulcerative colitis/ rheumatoid arthritis/ inflammation), Bristol-Myers Squibb/Medarex
    Click to Show/Hide
Status
Phase 2
TTD Drug ID
D00YWL
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
C-X-C motif chemokine 10 (CXCL10)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for BMS-936557. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of BMS-936557 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for BMS-936557. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-936557 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). [1], [2]
References
Ref 1 m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020 Oct 15;39(20):e104514. doi: 10.15252/embj.2020104514. Epub 2020 Sep 23.
Ref 2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029267)